New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
19:09 EDTCBST, AMRN, DRTX, ARTX, MDCO, VRNT, MDROn The Fly: After Hours Movers
HIGHER: Durata Therapeutics (DRTX), up 5.4% after an FDA Committee voted in favor of its Dalvance injection for the treatment of adult patients with acute bacterial skin and skin structure infections caused by certain bacteria... Amarin (AMRN), up 8.8% after announcing a co-promotion agreement with Kowa Pharmaceuticals America for its Vascepa capsules in the U.S... Verint Systems (VRNT), up 10% after reporting earnings that beat expectations and providing a fiscal year outlook that also topped estimates. LOWER: The Medicines Company (MDCO), down 14.3% after Durata and Cubist Pharmaceuticals (CBST) each received positive votes from FDA panels for bacteria treatments that could compete with its Oritavancin. Cubist (CBST), which confirmed the FDA panel vote intraday, saw shares gain $3.05, or 4.35%, to close at $73.15 for the session... Arotech (ARTX), down 12.5% after reporting fiscal year earnings and revenue that disappointed... McDermott (MDR), down 2.8% after filing to sell 10M tangible equity units and, in a separate release, saying that its first quarter results may differ "substantially" from the company's current expectation.
News For DRTX;MDR;MDCO;AMRN;VRNT;ARTX;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
06:46 EDTMDCOThe Medicines Co. upgraded to Buy from Neutral at Mizuho
Mizuho upgraded The Medicines Co. to Buy and raised its price target to $41 following last week's negative appeals court verdict that leads the way for Angiomax generics near-term. The firm believes consensus estimates still need to come down but believes an overhang has been removed and the focus should be on the company's many new launches and developmental compounds and collaboration potential.
06:41 EDTMDCOEagle Pharmaceuticals price target raised to $94 from $75 at Piper Jaffray
Subscribe for More Information
July 2, 2015
13:19 EDTMDCOCantor lowers sales assumptions for Eagle's Angiomax version
After an appeals court invalidated the Angiomax patents held by The Medicines Company (MDCO), Cantor Fitzgerald lowered its price target for Eagle Pharmaceuticals (EGRX) to $92 from $95 to reflect more modest sales assumptions for the company's version of Angiomax. Cantor had previously modeled a more favorable for Eagle whereby there were no generic entrants until 2019. The firm, however, still sees the stock as undervalued and keeps a Buy rating on the name.
12:40 EDTMDCOMedicines Co. says appeals court rules against company in Angiomax litigation
Subscribe for More Information
10:17 EDTMDCOAppeals court reverses lower court patent ruling in Medicines Co. case
The Medicines Company (MDCO) owns U.S. patent no. 7,582,727 and U.S. patent no. 7,598,343, which relate to the drug bivalirudin, a synthetic peptide used as an anti-coagulant that the company sells under the Angiomax brand. On August 19, 2010, The Medicines Company sued Hospira (HSP), alleging that two of Hospira’s ANDA filings infringe claims 1–3, 7–10, and 17 of the ’727 patent and claims 1–3 and 7–11 of the ’343 patent. A district court previously construed the asserted claims and, after a bench trial, found the patents not infringed and not invalid as obvious, indefinite, or under the on-sale bar. The Medicines Company appealed the U.S. District Court for the District of Delaware’s claim construction and non-infringement findings, while Hospira, crossappealed the district court’s determination that the asserted claims are not invalid under the on-sale bar, obviousness, or indefiniteness. The U.S. Court of Appeals for the Federal Circuit has now concluded that the district court "clearly erred" in finding that the bivalirudin batches prepared by Ben Venue Laboratories before the critical date were not sold to The Medicines Company and were prepared primarily for an experimental purpose. Accordingly, the federal appeals court reversed the district court’s validity determination and held the asserted claims invalid under the onsale bar. Shares of Medicines Co., which initially fell amid headlines regarding the ruling, are now up 4.5% to $29.61, while Hospira is flat at $88.90.
10:04 EDTMDCOHigh option volume stocks
Subscribe for More Information
09:57 EDTMDCOMedicines Co. loses appeal in Hospira suit over Angiomax patents, Bloomberg says
Subscribe for More Information
09:50 EDTMDCOThe Medicines Co. drops 3.2% to $27.43 in early trading
Subscribe for More Information
June 26, 2015
07:15 EDTMDCOMedicines Co. considering strategic options for European unit, Bloomberg reports
The Medicines Co. is working with advisers from Rothschild on a review of strategic options for its European business, according to Bloomberg, citing people familiar with the matter. The review, which is at an advanced stage, may lead to a sale, licensing agreement or partnership, the report added. Reference Link
June 25, 2015
14:38 EDTMDCOMedicines Co. considering strategic options for European unit, Bloomberg says
June 24, 2015
08:04 EDTARTXArotech's Training and Simulation division receives $8.7M in new orders
Arotech announced that its Training and Simulation Division has received $8.7M in new awards and contract modifications since the beginning of the second quarter. These orders are highlighted by $2.8M in funding for continued field support and capabilities upgrades to the U.S. Army's Virtual Clearance Training Suites, a $1.1M award for a York Region Rapid Transit Bus simulator, and a new international aircraft platform for its ZAP weapon employment software.
June 23, 2015
07:03 EDTMDRMcDermott awarded Otis Field Subsea Tieback Project by LLOG
McDermott International has been awarded a “sizeable lump sum contract” by LLOG Exploration Offshore in support of LLOG’s Otis development located in the Gulf of Mexico. The lump sum contract will be included in McDermott’s second quarter 2015 backlog. The Otis field, located in Block Mississippi Canyon 79, will be developed as a subsea tieback to the Delta House floating production system, or FPS, and lies in approximately 3,800 feet of water. McDermott’s Houston office will perform the overall project management and engineering. The flowline and SCR are scheduled to be assembled and fabricated at McDermott’s new spoolbase facility in Gulfport, Mississippi. Offshore installation is scheduled to be completed in early 2016.
June 22, 2015
16:37 EDTMDCOThe Medicines Co. to hold a conference call
Subscribe for More Information
14:33 EDTMDCOThe Medicines Co. antiplatelet drug approved by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use